SARS-CoV-2 Antibody Responses in 349 Symptomatic COVID-19 Patients Over Six Months

349 symptomatic COVID-19 patients were tracked for six months to quantify IgM and IgG antibody responses to SARS-CoV-2 spike and nucleocapsid proteins. The study, published as a medRxiv preprint by Jun Wu, found antibody positivity rates remained above 70% at the end of the observation period. Data likely includes longitudinal antibody titers, neutralizing activity, and patient clinical characteristics.

Use Cases

• Modeling the longevity of SARS-CoV-2 antibody responses based on longitudinal IgM and IgG titers.
• Correlating antibody levels with virus control based on RNA-positive versus RNA-negative patient groups.
• Analyzing the association between early antibody magnitude and disease severity or outcome.
• Studying the contraction and stabilization phases of IgG-S and IgG-N titers over time.

Strengths

• Longitudinal data spanning six months of follow-up from disease onset.
• Includes 349 confirmed symptomatic COVID-19 patients, providing a substantial cohort.
• Measures multiple antibody types (IgM-S, IgG-S, IgM-N, IgG-N) and neutralizing activities.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect temporal bias inherent to paperswithcode, focusing on early-pandemic infections.

Provenance

Source

Jun Wu (medRxiv preprint)

Collection Method

Clinical study quantifying antibodies via chemiluminescence immunoassays (CLIA) in patient plasma.

Time Range

Six months post-symptom onset